Overview

Ampligen Compared to No Treatment Following FOLFIRINOX in Subjects With Locally Advanced Pancreatic Adenocarcinoma

Status:
Not yet recruiting
Trial end date:
2027-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and efficacy of Ampligen in patients with locally advanced pancreatic adenocarcinoma
Phase:
Phase 2
Details
Lead Sponsor:
AIM ImmunoTech Inc.
Collaborator:
Amarex Clinical Research
Treatments:
poly(I).poly(c12,U)